Exagen Current Deferred Revenue from 2010 to 2024
| XGN Stock | USD 2.83 0.03 1.07% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 4.4 M | Current Value 3.7 M | Quarterly Volatility 1.6 M |
Check Exagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exagen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.8 M or Total Revenue of 32.2 M, as well as many indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0169 or PTB Ratio of 1.18. Exagen financial statements analysis is a perfect complement when working with Exagen Valuation or Volatility modules.
Exagen | Current Deferred Revenue |
Latest Exagen's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Exagen Inc over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Exagen's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exagen's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Exagen Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 3,390,510 | |
| Geometric Mean | 2,612,734 | |
| Coefficient Of Variation | 47.14 | |
| Mean Deviation | 1,184,604 | |
| Median | 3,842,000 | |
| Standard Deviation | 1,598,442 | |
| Sample Variance | 2.6T | |
| Range | 4.7M | |
| R-Value | 0.54 | |
| Mean Square Error | 1.9T | |
| R-Squared | 0.30 | |
| Significance | 0.04 | |
| Slope | 194,162 | |
| Total Sum of Squares | 35.8T |
Exagen Current Deferred Revenue History
About Exagen Financial Statements
Exagen investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Exagen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.4 M | 3.7 M |
Pair Trading with Exagen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.Moving against Exagen Stock
| 0.86 | ELEV | Elevation Oncology | PairCorr |
| 0.68 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
| 0.62 | INAB | In8bio Inc | PairCorr |
| 0.56 | KALA | Kala Pharmaceuticals | PairCorr |
| 0.55 | CGC | Canopy Growth Corp Upward Rally | PairCorr |
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Exagen Correlation against competitors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.